CA2669864A1 - Personalized therapeutic treatment process - Google Patents

Personalized therapeutic treatment process Download PDF

Info

Publication number
CA2669864A1
CA2669864A1 CA002669864A CA2669864A CA2669864A1 CA 2669864 A1 CA2669864 A1 CA 2669864A1 CA 002669864 A CA002669864 A CA 002669864A CA 2669864 A CA2669864 A CA 2669864A CA 2669864 A1 CA2669864 A1 CA 2669864A1
Authority
CA
Canada
Prior art keywords
dose
tissue
folate
ams
plasma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002669864A
Other languages
English (en)
French (fr)
Inventor
Ali Arjomand
Glenn Kawasaki
Michael Chansler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Accium Biosciences
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2669864A1 publication Critical patent/CA2669864A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002669864A 2006-11-17 2007-11-17 Personalized therapeutic treatment process Abandoned CA2669864A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85973906P 2006-11-17 2006-11-17
US60/859,739 2006-11-17
PCT/US2007/085033 WO2008064138A2 (en) 2006-11-17 2007-11-17 Personalized therapeutic treatment process

Publications (1)

Publication Number Publication Date
CA2669864A1 true CA2669864A1 (en) 2008-05-29

Family

ID=39430529

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002669864A Abandoned CA2669864A1 (en) 2006-11-17 2007-11-17 Personalized therapeutic treatment process

Country Status (7)

Country Link
EP (1) EP2094861A4 (OSRAM)
JP (1) JP2010510495A (OSRAM)
CN (1) CN101702921A (OSRAM)
AU (1) AU2007323782A1 (OSRAM)
BR (1) BRPI0719314A2 (OSRAM)
CA (1) CA2669864A1 (OSRAM)
WO (1) WO2008064138A2 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200116657A1 (en) * 2018-10-15 2020-04-16 Olaris, Inc. Nmr-metabolite-signature for identifying cancer patients resistant to cdk4/6 inhibitors, endocrine therapy and anti-her2 therapy

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0714040D0 (en) 2007-07-19 2007-08-29 Xceleron Ltd Quantification of analytes
CN105467108A (zh) * 2015-12-19 2016-04-06 开滦总医院 溶栓药物个体化应用剂量的体外测定试验方法
EP4046161A4 (en) * 2019-10-18 2023-11-29 National University of Singapore METHOD FOR PREDICTING APPROPRIATE THERAPY

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4131544A (en) * 1976-08-03 1978-12-26 Nasik Elahi Macroencapsulated sorbent element and process for using the same
US4880014A (en) * 1987-08-14 1989-11-14 Zarowitz Barbara J Method for determining therapeutic drug dosage using bioelectrical resistance and reactance measurements
GB0304433D0 (en) * 2003-02-27 2003-04-02 Xceleron Ltd Improvements relating to chemical libraries
EP1608966A2 (en) * 2003-04-02 2005-12-28 Celator Pharmaceuticals, Inc. Methods to individualize combination therapy
ATE506011T1 (de) * 2004-09-20 2011-05-15 Resonant Medical Inc Radiotherapiebehandlungsüberwachung unter einsatz von ultraschall
EP1810315B1 (en) * 2004-10-28 2014-12-03 Albert Edward Litherland Method and apparatus for separation of isobaric interferences
GB0504243D0 (en) * 2005-03-02 2005-04-06 Xceleron Ltd Biological compositions labelled with radioisotope

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200116657A1 (en) * 2018-10-15 2020-04-16 Olaris, Inc. Nmr-metabolite-signature for identifying cancer patients resistant to cdk4/6 inhibitors, endocrine therapy and anti-her2 therapy

Also Published As

Publication number Publication date
WO2008064138A2 (en) 2008-05-29
CN101702921A (zh) 2010-05-05
BRPI0719314A2 (pt) 2014-02-04
JP2010510495A (ja) 2010-04-02
EP2094861A2 (en) 2009-09-02
AU2007323782A1 (en) 2008-05-29
EP2094861A4 (en) 2010-03-17
WO2008064138A3 (en) 2009-01-15

Similar Documents

Publication Publication Date Title
Poirier et al. Carcinogen macromolecular adducts and their measurement
Wittig et al. Boron analysis and boron imaging in biological materials for boron neutron capture therapy (BNCT)
Wang et al. MDM2-NFAT1 dual inhibitor, MA242: Effective against hepatocellular carcinoma, independent of p53
Medici et al. Impaired homocysteine transsulfuration is an indicator of alcoholic liver disease
JP2007524835A (ja) ｉｎｖｉｖｏにおいて単一プロトコルにより２以上の生体分子の相対流速を比較する方法
Chetta et al. Metabolic reprogramming as an emerging mechanism of resistance to endocrine therapies in prostate cancer
Watanabe et al. Metabolic profiling comparison of human pancreatic ductal epithelial cells and three pancreatic cancer cell lines using NMR based metabonomics
Kyriakides et al. Comparative metabonomic analysis of hepatotoxicity induced by acetaminophen and its less toxic meta-isomer
Fujimura et al. Mass spectrometry-based metabolic profiling of gemcitabine-sensitive and gemcitabine-resistant pancreatic cancer cells
Oh et al. Radio-copper-labeled Cu-ATSM: an indicator of quiescent but clonogenic cells under mild hypoxia in a Lewis lung carcinoma model
Madeen et al. Human in vivo pharmacokinetics of [14C] dibenzo [def, p] chrysene by accelerator mass spectrometry following oral microdosing
Green et al. Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-β inhibitor
CA2669864A1 (en) Personalized therapeutic treatment process
Gausdal et al. Abolition of stress-induced protein synthesis sensitizes leukemia cells to anthracycline-induced death
Skowron et al. Targeting CLDN6 in germ cell tumors by an antibody-drug-conjugate and studying therapy resistance of yolk-sac tumors to identify and screen specific therapeutic options
AU2014202609A1 (en) Personalized therapeutic treatment process
Smith et al. Treatment of breast tumor cells in vitro with the mitochondrial membrane potential dissipater valinomycin increases 18F-FDG incorporation
US11474106B2 (en) Methods for cytotoxic chemotherapy-based predictive assays
Kim et al. In vivo measurement of DNA synthesis rates of colon epithelial cells in carcinogenesis
Coudray et al. Stable isotopes in studies of intestinal absorption, exchangeable pools and mineral status: The example of magnesium
US20200010910A1 (en) Cytotoxic Chemotherapy-Based Predictive Assays for Acute Myeloid Leukemia
Jiménez-Cortegana et al. Cytofluorometric assessment of cell cycle progression in irradiated cells
Chen et al. Accelerator mass spectrometry measurement of intracellular concentrations of active drug metabolites in human target cells in vivo
Li et al. Asiatic acid induces lung cancer toxicity by triggering src-mediated ferroptosis
Chen et al. Anti-tumour and associated metabolic effects of repurposed Afuresertib and Taxifolin for glioblastoma treatment

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20141118